Collegium Pharmaceutical (COLL) EBITDA (2014 - 2026)

Collegium Pharmaceutical's EBITDA history runs 13 years deep, the most recent figure standing at $30.9 million for Q1 2026.

• On a quarterly basis, EBITDA rose 42.46% year-over-year to $30.9 million in Q1 2026; TTM through Mar 2026 was $188.8 million, a 32.89% increase from a year earlier, with the FY2025 full-year figure at $179.6 million, up 5.73% from the prior year.
• EBITDA fell to $30.9 million in Q1 2026 per COLL's latest filing, from $60.8 million in the prior quarter.
• Across five years, EBITDA topped out at $62.1 million in Q3 2025 and bottomed at -$10.0 million in Q1 2022.
• The 5-year median for EBITDA is $35.1 million (2025), against an average of $34.2 million.
• Across the five-year window, EBITDA plunged 147.26% in 2022 and jumped 424.69% in 2023, its largest moves.
• Year by year, EBITDA stood at $11.8 million in 2022, then soared by 424.69% to $61.7 million in 2023, then slumped by 38.22% to $38.1 million in 2024, then surged by 59.42% to $60.8 million in 2025, then sank by 49.15% to $30.9 million in 2026.
• Per Business Quant, the three latest COLL EBITDA figures stand at $30.9 million (Q1 2026), $60.8 million (Q4 2025), and $62.1 million (Q3 2025).